Lupin, Enzene Biosciences Announce Strategic Partnership to launch Cetuximab in India

Enzene Biosciences and Lupin Limited have announced a strategic alliance to introduce Cetuximab, the first biosimilar created for Cetuximab, in India. The expansion of therapeutic options and promotion of innovation in the crucial area of head and neck cancer treatment are made possible by this collaboration. A significant treatment option for patients with recurrent locoregional or metastatic disease is cetuximab, which has been approved by the Drug Controller General of India (DCGI) for the management of head and neck cancer, specifically squamous cell carcinoma of the head and neck (SCCHN).

A 100mg vial of cetuximab is available. With a staggering annual incidence of over 100,000 new cases, head and neck cancer poses a significant public health challenge in India. This cancer affects vital areas of the head and neck, such as the oral cavity, pharynx, larynx, and sinuses. Because the disease is frequently diagnosed at an advanced stage, effective treatment is becoming increasingly difficult. As a result, head and neck cancer carries a significant burden, making effective treatment difficult and resulting in high mortality rates. "Through this collaboration, we empower healthcare professionals with a transformative and affordable solution that has the potential to make a significant impact on the lives of those facing this challenging disease," said Rajeev Sibal, President, India Region Formulations, Lupin.